Market Place
Sourcing Support
Cyclacel To Present Fadraciclib Data At EORTC-NCI-AACR Symposium
09 Oct 2024 //
GLOBENEWSWIRE
Cyclacel Completes Enrollment In Phase 2 Study Cohort
25 Sep 2024 //
GLOBENEWSWIRE
Cyclacel To Participate In H.C. Wainwright Conference
04 Sep 2024 //
GLOBENEWSWIRE
Cyclacel: Fadraciclib Efficacy In Colorectal Cancer Models At ASCO 2024
04 Jun 2024 //
GLOBENEWSWIRE
Cyclacel`s Fadraciclib Precision Cancer Med Potential At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
Cyclacel to Present New Clinical Data at ASCO Meeting Highlighting Fadraciclib
01 Apr 2024 //
GLOBENEWSWIRE
Cyclacel Announces Preclinical Data for Fadraciclib to be Presented
07 Mar 2024 //
GLOBENEWSWIRE
Cyclacel Pharmaceuticals Reports Fadraciclib Phase 1 Data
18 Dec 2023 //
GLOBENEWSWIRE
Cyclacel To Present Preliminary Data From The P1/2 Trial Of Oral Fadraciclib
13 Oct 2022 //
GLOBENEWSWIRE
Cyclacel Pharma to Publish Confirming Fadraciclib Suppresses MCL1 and CLL
12 Apr 2022 //
GLOBENEWSWIRE
Cyclacel Begins Dosing in Phase 1/2 Study of Fadraciclib in Leukemias or MDS
05 Nov 2021 //
GLOBENEWSWIRE
Cyclacel Announces Fadraciclib Abstract Selected for Oral Presentation
21 Sep 2020 //
GLOBENEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.